Preventive Protocols for Extraction in Antiresorptive Patients

What the evidence says

Tooth extraction is a well-established primary risk factor for medication-related osteonecrosis of the jaw (MRONJ) in people taking antiresorptive drugs. In one retrospective cohort, 62% of MRONJ-positive patients had undergone tooth extraction, against 35% of MRONJ-negative patients (p < 0.05). Protocols for extraction in these patients vary across practices and are not universally standardised, so "the protocol" is not one fixed intervention in this literature.

Packages of preventive measures are associated with lower osteonecrosis (ONJ) incidence in every source here that measures it. A meta-analysis reports a 77.3% reduction in ONJ compared with control groups. A review reports the same 77.3% figure for combined dental exam, hygiene and oral care. Individual studies report reductions from 26.3% to 6.7% with zoledronic acid, from 3.2% to 1.3% with intravenous bisphosphonates, and from 4.6% to 0.8% for comprehensive dental care before treatment starts. The authors of the meta-analysis note poor quality of evidence in most source articles and high heterogeneity. The direction is consistent across studies. The size of the reduction depends heavily on the baseline rate and the design.

Timing and frequency of dental care also show an association. Preventive treatment before bisphosphonate use, combined with dental follow-up at 3 months, reduced ONJ from 22.3% to 2.2% compared with annual follow-up. That study is prospective but single-center, with possible selection bias. A randomized trial inside the Gharibi review reports a reduction in MRONJ with regular examinations every three months, but gives no magnitude.

For specific components, the evidence is thinner. Antibiotic prophylaxis during extraction is associated with lower ONJ risk. A prospective case series pairing it with atraumatic technique reports 0% ONJ after extraction, but it has a small sample and no control group. Reviewed regimens vary (2–3 g amoxicillin, 3–20 days), so no single regimen is established. Low-level laser therapy is reported to reduce MRONJ cases by 2.5%, with heterogeneous protocols. Nd:YAG laser combined with antibiotics is reported to reduce ONJ rate in cancer patients on bisphosphonates, with no magnitude given. The laser effect cannot be separated from the antibiotic effect. Autologous platelet concentrates showed no MRONJ over long follow-up in implant surgery in patients on low-dose antiresorptives. That evidence comes from a small sample and is limited to low-dose regimens.

Drug holidays show no measured effect. A review reports no difference in MRONJ risk between continuing and pausing antiresorptives, with heterogeneous methods and limited head-to-head comparisons.

One imaging proposal is untested. Lamina dura (LD) thickening alone showed no association with MRONJ (p = 0.39). The authors speculate that combining it with extraction could raise risk. They also speculate that recognizing it could prompt antibiotics, leukocyte- and platelet-rich fibrin (LPRF), or a drug holiday. None of this was tested.

Where the evidence splits

No contradictions in the current sources.

Thresholds and dose-response

No threshold established in the current sources.

Open empirical questions

• Which single component of the preventive packages (antibiotics, atraumatic technique, follow-up, laser) produces the reduction, since the sources test them mostly in combination?
• Does the 77.3% reduction hold in controlled studies with concurrent control groups, given the poor quality of evidence in most source articles?
• Does a drug holiday change MRONJ incidence in a head-to-head comparison across different antiresorptive agents?
• Does adding LD thickening to extraction increase MRONJ risk, and does acting on it change outcomes?